Barclays PLC Travere Therapeutics, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Barclays PLC holds 168,768 shares of TVTX stock, worth $2.9 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

168,768

Previous 168,768 -0.0%

Holding current value

$2.9 Million

Previous $2.36 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	SELL	$7.89 - $15.21 $138,422 - $266,844	-17,544 Reduced 9.42%	168,768 $2.36 Million
Q2 2024 Aug 14, 2024	BUY	$5.26 - $8.28 $44,999 - $70,835	8,555 Added 4.81%	186,312 $1.53 Million
Q1 2024 May 15, 2024	SELL	$7.18 - $9.82 $1.5 Million - $2.05 Million	-209,052 Reduced 54.05%	177,757 $1.37 Million
Q4 2023 Feb 15, 2024	BUY	$5.44 - $9.5 $533,963 - $932,472	98,155 Added 34.0%	386,809 $3.48 Million
Q3 2023 Nov 07, 2023	BUY	$7.64 - $17.25 $275,582 - $622,224	36,071 Added 14.28%	288,654 $2.58 Million
Q2 2023 Aug 03, 2023	BUY	$15.3 - $22.61 $761,894 - $1.13 Million	49,797 Added 24.56%	252,583 $3.88 Million
Q1 2023 May 04, 2023	BUY	$17.82 - $22.89 $320,760 - $412,020	18,000 Added 9.74%	202,786 $4.56 Million
Q4 2022 Feb 13, 2023	BUY	$18.47 - $26.14 $884,214 - $1.25 Million	47,873 Added 34.97%	184,786 $3.89 Million
Q3 2022 Nov 03, 2022	BUY	$22.91 - $28.63 $2.55 Million - $3.19 Million	111,357 Added 435.74%	136,913 $3.37 Million
Q2 2022 Aug 12, 2022	SELL	$20.94 - $30.01 $488,844 - $700,583	-23,345 Reduced 47.74%	25,556 $619,000
Q1 2022 May 16, 2022	BUY	$23.61 - $30.6 $1.15 Million - $1.5 Million	48,901 New	48,901 $1.26 Million

Others Institutions Holding TVTX

# of Institutions

193

Shares Held

84.6M

Call Options Held

776K

Put Options Held

900K

View Full List

About Travere Therapeutics, Inc.

Ticker TVTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,173,600
Market Cap $1.1B
Description
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...

More about TVTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account